<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968019</url>
  </required_header>
  <id_info>
    <org_study_id>08-CR-001</org_study_id>
    <nct_id>NCT00968019</nct_id>
  </id_info>
  <brief_title>Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion Stent</brief_title>
  <official_title>A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions. Iberian Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson and Johnson, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson and Johnson, S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is: To evaluate the safety and performance of the Presillion stent
      in routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: Composite of Major Adverse Cardiac Events (MACE), which includes cardiac
      death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion
      revascularization (TLR) at 12 months follow-up.

      Data will be collected on 400 patients (from 14 hospitals in Spain and Portugal) treated with
      the Presillion stent in up to 2 de novo native coronary artery lesions

      Study design: multicenter, prospective, observational
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Cardiac Adverse Events (Including Cardiac Death, Myocardial Infarction (Q-wave and Non Q-wave) and Clinically Driven TLR (Target Lesion Revascularization))</measure>
    <time_frame>at 12 months follow-up</time_frame>
    <description>Major adverse cardiac and cerebral events are defined as an adjudicated composite of cardiac death, myocardial infarction (Q-wave and non Q-wave), emergent coronary artery bypass surgery and target vessel revascularization (TVR).
The primary safety measure was the composite of MACE up to 12 months follow up. In order to show the safety of the device, the MACE rate was compared with the performance goal for bare metal stents(experience with bare metal stents in clinical trials suggested that the 12 month MACE rate should be about 25.0%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Peri-procedure up to discharge</time_frame>
    <description>Device success defined as achievement of a final diameter stenosis of &lt;50% (by visual estimate), using the assigned device only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>Peri-procedure up to discharge</time_frame>
    <description>Lesion success defined as the attainment of &lt;50% final diameter stenosis (by visual estimate) using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Peri-procedure up to discharge</time_frame>
    <description>Procedural success defined as achievement of a final diameter stenosis of &lt;50% (by visual estimate) using any percutaneous method, without the occurrence of death, MI (Myocardial Infarction), or repeat revascularization of the target lesion during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven TLR</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven TVR</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
MI occurs in territory not clearly attributed to a vessel other than the target vessel.
Cardiac death not clearly due to a non-target vessel endpoint.
Target vessel revascularization is performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
ischemic symptoms
ECG changes indicative of ischemia (ST segment elevation or depression)
Development of pathological Q waves in the ECG
Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
Pathological findings of an acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven TLR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven TVR</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
MI occurs in territory not clearly attributed to a vessel other than the target vessel.
Cardiac death not clearly due to a non-target vessel endpoint.
Target vessel revascularization is performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
ischemic symptoms
ECG changes indicative of ischemia (ST segment elevation or depression)
Development of pathological Q waves in the ECG
Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
Pathological findings of an acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">318</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Presillion stent</arm_group_label>
    <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Presillion stent</intervention_name>
    <description>Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).</description>
    <arm_group_label>Presillion stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All sujects treated with Presillion stent up to two de novo coronary artery lesions
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects treated with Presillion stent up to two de novo coronary artery lesions

        Exclusion Criteria:

          -  No specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Cequier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Garcia Da Orta</name>
      <address>
        <city>Almada</city>
        <zip>2805-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Lisbon</city>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Vila Real</name>
      <address>
        <city>Vila Real</city>
        <zip>5000 - 508</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio Hospital General de Catalu√±a</name>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <results_first_submitted>January 15, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2013</results_first_posted>
  <last_update_submitted>March 5, 2013</last_update_submitted>
  <last_update_submitted_qc>March 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treated With Presillion Stent</title>
          <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated With Presillion Stent</title>
          <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="318"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Cardiac Adverse Events (Including Cardiac Death, Myocardial Infarction (Q-wave and Non Q-wave) and Clinically Driven TLR (Target Lesion Revascularization))</title>
        <description>Major adverse cardiac and cerebral events are defined as an adjudicated composite of cardiac death, myocardial infarction (Q-wave and non Q-wave), emergent coronary artery bypass surgery and target vessel revascularization (TVR).
The primary safety measure was the composite of MACE up to 12 months follow up. In order to show the safety of the device, the MACE rate was compared with the performance goal for bare metal stents(experience with bare metal stents in clinical trials suggested that the 12 month MACE rate should be about 25.0%).</description>
        <time_frame>at 12 months follow-up</time_frame>
        <population>No formal statistical significance testing was performed. Descriptive statistics were calculated for all relevant variables (mean, standard deviation, median and ranges for the continuous variables and with frequencies and % for the discrete variables). Subjects who discontinued prematurely were included in the analysis and were not replaced.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Major Cardiac Adverse Events (Including Cardiac Death, Myocardial Infarction (Q-wave and Non Q-wave) and Clinically Driven TLR (Target Lesion Revascularization))</title>
          <description>Major adverse cardiac and cerebral events are defined as an adjudicated composite of cardiac death, myocardial infarction (Q-wave and non Q-wave), emergent coronary artery bypass surgery and target vessel revascularization (TVR).
The primary safety measure was the composite of MACE up to 12 months follow up. In order to show the safety of the device, the MACE rate was compared with the performance goal for bare metal stents(experience with bare metal stents in clinical trials suggested that the 12 month MACE rate should be about 25.0%).</description>
          <population>No formal statistical significance testing was performed. Descriptive statistics were calculated for all relevant variables (mean, standard deviation, median and ranges for the continuous variables and with frequencies and % for the discrete variables). Subjects who discontinued prematurely were included in the analysis and were not replaced.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Device success defined as achievement of a final diameter stenosis of &lt;50% (by visual estimate), using the assigned device only</description>
        <time_frame>Peri-procedure up to discharge</time_frame>
        <population>318 patients treated with the Presillion stent in up to two de novo coronary artery lesions (354 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Device success defined as achievement of a final diameter stenosis of &lt;50% (by visual estimate), using the assigned device only</description>
          <population>318 patients treated with the Presillion stent in up to two de novo coronary artery lesions (354 lesions)</population>
          <units>percentage of device success</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success</title>
        <description>Lesion success defined as the attainment of &lt;50% final diameter stenosis (by visual estimate) using any percutaneous method.</description>
        <time_frame>Peri-procedure up to discharge</time_frame>
        <population>318 patients treated with the Presillion stent in up to two de novo coronary artery lesions (354 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Success</title>
          <description>Lesion success defined as the attainment of &lt;50% final diameter stenosis (by visual estimate) using any percutaneous method.</description>
          <population>318 patients treated with the Presillion stent in up to two de novo coronary artery lesions (354 lesions)</population>
          <units>percentage of lesion Success</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesion</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success defined as achievement of a final diameter stenosis of &lt;50% (by visual estimate) using any percutaneous method, without the occurrence of death, MI (Myocardial Infarction), or repeat revascularization of the target lesion during the hospital stay</description>
        <time_frame>Peri-procedure up to discharge</time_frame>
        <population>318 patients treated with the Presillion stent in up to two de novo coronary artery lesions (354 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success defined as achievement of a final diameter stenosis of &lt;50% (by visual estimate) using any percutaneous method, without the occurrence of death, MI (Myocardial Infarction), or repeat revascularization of the target lesion during the hospital stay</description>
          <population>318 patients treated with the Presillion stent in up to two de novo coronary artery lesions (354 lesions)</population>
          <units>percentage of Procedural Success</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Driven TLR</title>
        <description>Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel</description>
        <time_frame>Up to 30 days</time_frame>
        <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven TLR</title>
          <description>Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel</description>
          <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Driven TVR</title>
        <description>Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven TVR</title>
          <description>Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.</description>
          <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure</title>
        <description>Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
MI occurs in territory not clearly attributed to a vessel other than the target vessel.
Cardiac death not clearly due to a non-target vessel endpoint.
Target vessel revascularization is performed.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure</title>
          <description>Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
MI occurs in territory not clearly attributed to a vessel other than the target vessel.
Cardiac death not clearly due to a non-target vessel endpoint.
Target vessel revascularization is performed.</description>
          <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
ischemic symptoms
ECG changes indicative of ischemia (ST segment elevation or depression)
Development of pathological Q waves in the ECG
Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
Pathological findings of an acute myocardial infarction</description>
        <time_frame>Up to 30 days</time_frame>
        <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
ischemic symptoms
ECG changes indicative of ischemia (ST segment elevation or depression)
Development of pathological Q waves in the ECG
Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
Pathological findings of an acute myocardial infarction</description>
          <population>309 patients treated with the Presillion stent in up to two de novo coronary artery lesions (311 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding</title>
        <time_frame>Up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <time_frame>Up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.</description>
        <time_frame>Up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Driven TLR</title>
        <description>Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel</description>
        <time_frame>up to 12 months</time_frame>
        <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven TLR</title>
          <description>Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel</description>
          <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Driven TVR</title>
        <description>Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven TVR</title>
          <description>Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.</description>
          <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure</title>
        <description>Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
MI occurs in territory not clearly attributed to a vessel other than the target vessel.
Cardiac death not clearly due to a non-target vessel endpoint.
Target vessel revascularization is performed.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure</title>
          <description>Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
MI occurs in territory not clearly attributed to a vessel other than the target vessel.
Cardiac death not clearly due to a non-target vessel endpoint.
Target vessel revascularization is performed.</description>
          <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
ischemic symptoms
ECG changes indicative of ischemia (ST segment elevation or depression)
Development of pathological Q waves in the ECG
Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
Pathological findings of an acute myocardial infarction</description>
        <time_frame>Up to 12 months</time_frame>
        <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
ischemic symptoms
ECG changes indicative of ischemia (ST segment elevation or depression)
Development of pathological Q waves in the ECG
Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
Pathological findings of an acute myocardial infarction</description>
          <population>303 patients treated with the Presillion stent in up to two de novo coronary artery lesions (308 lesions)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated With Presillion Stent</title>
            <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated With Presillion Stent</title>
          <description>Patients treated with the Presillion stent in up to two de novo coronary artery lesions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Serious Adverse Events not related to the study device</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Revascularization</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bleeding or vascular event</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Signs that do not interfere, or interferes but does not hinder, with the subject‚Äôs usual activity</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>since the difference with the performance goal is this large; the possibility of underreporting of adverse events is something that needs to be considered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mayda Lopez-Belmonte, PhD</name_or_title>
      <organization>Johnson and Johnson Medical Iberia</organization>
      <phone>+34 91 7228481</phone>
      <email>tlopezbe@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

